Published in PLoS One on July 06, 2012
The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. J Thromb Haemost (2013) 1.02
Syntaxin-binding protein STXBP5 inhibits endothelial exocytosis and promotes platelet secretion. J Clin Invest (2014) 0.93
Platelet secretion and hemostasis require syntaxin-binding protein STXBP5. J Clin Invest (2014) 0.89
Syntaxin-binding protein 5 exocytosis regulation: differential role in endothelial cells and platelets. J Clin Invest (2014) 0.78
Genome-wide association studies identify genetic loci for low von Willebrand factor levels. Eur J Hum Genet (2015) 0.76
Novel Thrombotic Function of a Human SNP in STXBP5 Revealed by CRISPR/Cas9 Gene Editing in Mice. Arterioscler Thromb Vasc Biol (2016) 0.75
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation (2010) 2.78
Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med (2005) 2.16
The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood (2007) 2.07
Letter: A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh (1975) 1.59
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood (2008) 1.53
von Willebrand factor. FASEB J (1993) 1.47
An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost (2006) 1.39
Tomosyn interacts with the t-SNAREs syntaxin4 and SNAP23 and plays a role in insulin-stimulated GLUT4 translocation. J Biol Chem (2003) 1.32
Old concepts and new developments in the study of platelet aggregation. J Clin Invest (2000) 1.22
Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet (2010) 1.01
Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost (2007) 0.93
Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program (2009) 0.92
Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA (2006) 4.75
Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med (2012) 3.05
Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation (2010) 2.78
Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA (2006) 2.15
C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. Eur Heart J (2006) 2.04
Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes (2007) 1.86
Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation (2005) 1.78
The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood (2011) 1.67
High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke (2010) 1.64
An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men. Clin Sci (Lond) (2004) 1.61
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood (2010) 1.61
Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost (2008) 1.61
Cardiovascular risk assessment in haemophilia patients. Thromb Haemost (2010) 1.57
Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood (2013) 1.51
Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch. Transfusion (2006) 1.50
Genetic variation in the fibrinogen-alpha and fibrinogen-gamma genes in relation to arterial stiffness: the Rotterdam Study. J Hypertens (2009) 1.49
PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost (2008) 1.42
High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke (2006) 1.37
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood (2012) 1.29
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology (2006) 1.28
Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J (2005) 1.16
The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort study. Chest (2007) 1.12
Fibrinogen gamma' in ischemic stroke: a case-control study. Stroke (2008) 1.10
Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica (2006) 1.08
Diagnosis and management of haemophilia. BMJ (2012) 1.07
Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs (2002) 1.05
The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med (2003) 1.04
Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol (2009) 1.03
Haemostatic abnormalities in patients with liver disease. J Hepatol (2002) 1.02
Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet (2010) 1.01
Effects of ambient air pollution on hemostasis and inflammation. Environ Health Perspect (2009) 0.99
Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol (2002) 0.98
Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica (2007) 0.98
Comparison of two methods for selection of out of hospital treatment in patients with acute pulmonary embolism. Thromb Haemost (2012) 0.97
Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood (2010) 0.96
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood (2013) 0.96
Elevated fibrinogen gamma' ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome. Blood (2009) 0.96
Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol (2004) 0.94
γ'/total fibrinogen ratio is associated with short-term outcome in ischaemic stroke. Thromb Haemost (2010) 0.94
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J (2010) 0.94
A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke. Int J Stroke (2010) 0.93
Yellow fever vaccination as a model to study the response to stimulation of the inflammation system. Vascul Pharmacol (2002) 0.93
A hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for interleukin 6-induced expression, and its activity is influenced by the adjacent -148C/T polymorphism. J Biol Chem (2005) 0.93
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost (2010) 0.93
Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg (2007) 0.93
Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet (2009) 0.92
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J (2011) 0.91
Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia? Blood Cells Mol Dis (2009) 0.90
-455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost (2005) 0.90
Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost (2005) 0.90
Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation. Circulation (2010) 0.89
Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. Clin Lymphoma Myeloma (2007) 0.88
Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention. J Am Coll Cardiol (2005) 0.87
Identification of fibrin clot-bound plasma proteins. PLoS One (2012) 0.86
Anticoagulant effect of dietary fish oil in hyperlipidemia: a study of hepatic gene expression in APOE2 knock-in mice. Arterioscler Thromb Vasc Biol (2008) 0.86
Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention. Expert Opin Ther Targets (2010) 0.86
Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease. Br J Nutr (2008) 0.86
Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary intervention. Pharmacogenet Genomics (2006) 0.85
CRP gene haplotypes, serum CRP, and cerebral small-vessel disease: the Rotterdam Scan Study and the MEMO Study. Stroke (2007) 0.85
Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood (2009) 0.84
Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol (2009) 0.84
Polymorphisms and haplotypes in the C-reactive protein gene and risk of dementia. Neurobiol Aging (2006) 0.84
Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost (2010) 0.84
Fish oil consumption and reduction of arterial disease. J Nutr (2003) 0.84
Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis (2013) 0.84
Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndrome. Dis Markers (2009) 0.83
Genetics of C-reactive protein: new possibilities and complications. Arterioscler Thromb Vasc Biol (2003) 0.83
The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals. Atherosclerosis (2005) 0.83
Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res (2008) 0.83
Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. Diabetes Care (2005) 0.83
Genetic variation in Fcgamma receptor IIa protects against advanced peripheral atherosclerosis. The Rotterdam Study. Thromb Haemost (2004) 0.83
Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol (2011) 0.83
Fibrinogen gene haplotypes in relation to risk of coronary events and coronary and extracoronary atherosclerosis: the Rotterdam Study. Thromb Haemost (2007) 0.82
Internal quality control of PCR-based genotyping methods in research studies and patient diagnostics. Thromb Haemost (2002) 0.82
Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: the Rotterdam Study. Neurobiol Aging (2008) 0.82
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion. Eur J Haematol (2004) 0.82
Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Results of the ATHEROREMO-IVUS study. Thromb Haemost (2014) 0.82
Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost (2012) 0.81